Pfizer Inc. Stock
€27.88
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.760% | 0.765% | 4.752% | -18.392% | 5.996% | -21.894% | -24.065% |
| Johnson & Johnson | 0.610% | 0.740% | 3.830% | -6.774% | 1.850% | -1.179% | 23.794% |
| Elanco Animal Health Inc. | 1.530% | -1.607% | -30.491% | 7.835% | -13.062% | -62.096% | - |
| Biogen Inc. | -0.380% | -0.144% | -1.185% | -16.733% | -11.578% | -24.525% | -3.828% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
If you're looking to invest in order to get richer, that's great -- because most of us need to be amassing a war chest for retirement (not to mention other financial goals, such as a down payment
Beware, Wegovy -- Pfizer Is Working on a Competitor
Which company is the leader in the burgeoning weight loss drug market? A recent poll found that among the largest drugmakers, Pfizer (NYSE: PFE) is the one Americans associate most with this
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
If there's one thing healthcare giant Pfizer (NYSE: PFE) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are